Treatment of undescended testes with intranasal application of synthetic LH-RH
β Scribed by S. Hagberg; O. Westphal
- Publisher
- Springer
- Year
- 1982
- Tongue
- English
- Weight
- 275 KB
- Volume
- 139
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
β¦ Synopsis
The effect of intranasal, synthetic LH-RH (Hoe 471) on undescended testes was investigated in: I. a double blind study comprising 50 patients given either placebo or 0.6 mg LH-RH daily and II. an open study comprising 50 patients with a daily dosage of 1.2 mg LH-RH. In both studies LH-RH was given for 4 weeks. Since some patients had bilateral undescended testes, 116 testes were treated in total. Patients' ages varied between 1 1/2 and 10 1/2 years, with a mean of 5 years. Clinical examination before, during and at end of treatment was performed by both the authors independently. In the placebo group, one testicular descent was seen, indicating difficulty in diagnosis. A therapeutic result, i.e. a significant move from the pretreatment location towards the bottom of the scrotum was seen in 60% of the testes, complete descent being seen in about 40%. In a follow-up study 6 months after treatment, in 23 cases with complete descent from a pretreatment inguinal position, relapse was seen in 5 patients (2 were located at scrotal neck, 3 at the pretreatment position i.e. inguinal). The best results were seen on testes located not too far from the scrotal neck, with the higher dosage of LH-RH and in patients less than 6 years of age. No significant hormonal changes (testosterone-, LH- or FSH-levels in peripheral blood) were seen during the study. Side effects were negligible.
π SIMILAR VOLUMES
Sixty-seven prepubertal boys with either uni-or bilateral cryptorchidism were treated with LH-RH or its analogue Hoe 766. In all cases the undescended testes were located in the inguinal canal; none had retractile testes. A) 23 boys were given 200 lag LH-RH-6 times daily for 7 days B) 24 boys were
Fourteen prepubertM boys (aged 5--14 years) with either unilateral or bilateral undescended testes and 2 males (aged 17 and 18 years) with hypopituitarism received human ehorionie gonadotropin (HCG) either in high doses for a short (3 day) period (6 subjects) or in low doses for a long (2---6 week)